Skip to main content


Figure 2 | Retrovirology

Figure 2

From: In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy

Figure 2

Increasing the number of shRNAs. Tx and UNTx, infected and uninfected cells are expressed as a percentage of all cells and monitored over 5000 days. Scenarios include; A) The absence of gene therapy B) 6 shRNAs (S1), C) 4 shRNAs (S2) and D) 2 shRNAs (S3). Assumptions for each scenario include 80n % efficacy (80e), 20% Tx hematopoietic stem cells containing the gene therapeutic (HSC+), 99% fitness (99f) with Class I and II inhibition.

Back to article page